Biohaven (NYSE:BHVN) Shares Down 7.4% - What's Next?

Key Points

• Biohaven shares fell 7.4% to about $15.70, despite recent positive developments, including a licensing agreement with SK Biopharmaceuticals for its Kv7 epilepsy platform worth up to $795 million plus royalties.
• The company’s outlook remains dependent on execution: the deal’s headline value is milestone-based, while investors await RISE3 epilepsy data and obesity-trial results expected later in 2026.
• Analysts maintain a broadly positive view, with a “Moderate Buy” consensus and an $18.94 price target, although Biohaven recently missed quarterly earnings estimates and remains unprofitable.

Biohaven Ltd. (NYSE:BHVN - Get Free Report) shares fell 7.4% on Thursday . The stock traded as low as $15.50 and last traded at $15.7030. Approximately 699,601 shares changed hands during trading, a decline of 73% from the average session volume of 2,627,393 shares. The stock had previously closed at $16.95.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: SK Biopharmaceuticals licensing deal: Biohaven granted SK Biopharmaceuticals global rights to its Kv7 ion-channel platform, including opakalim, its lead candidate for focal epilepsy. The agreement provides for upfront and milestone payments totaling up to $795 million, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation of epilepsy platform: Opakalim is in Phase 2/3 development, with topline RISE3 trial results expected in the second half of 2026. The partnership gives Biohaven a global development and commercial partner while preserving potential royalty income. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court formally confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, resulting in a $4 million award to Biohaven and Yale. The ruling provides a legal and financial benefit, although it is considerably smaller than the potential licensing proceeds. Federal court trade-secret judgment
• Neutral Sentiment: Upcoming data remains a key catalyst: Investors are now focused on the RISE3 epilepsy readout and the company’s upcoming obesity-trial results. Positive data could support further gains, while delays or disappointing results could increase volatility. BHVN market reaction and upcoming trial readouts
• Negative Sentiment: Milestone-dependent economics: The headline $795 million amount is a maximum potential value rather than guaranteed near-term revenue. Biohaven must still achieve clinical and regulatory milestones, leaving execution and trial risk in the stock’s valuation. The Pharma Letter licensing coverage

Wall Street Analyst Weigh In

BHVN has been the topic of a number of recent analyst reports. Wall Street Zen raised Biohaven from a "strong sell" rating to a "sell" rating in a research report on Saturday, June 27th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Biohaven in a research report on Friday, June 26th. Royal Bank Of Canada lifted their price target on Biohaven from $22.00 to $23.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 11th. HC Wainwright restated a "neutral" rating on shares of Biohaven in a report on Thursday. Finally, TD Cowen reiterated a "buy" rating on shares of Biohaven in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $18.94.

Biohaven Stock Performance

The stock has a market capitalization of $2.40 billion, a PE ratio of -3.37 and a beta of 1.26. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. The firm has a 50 day moving average of $14.74 and a 200-day moving average of $11.83.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.15). Research analysts forecast that Biohaven Ltd. will post -3.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BHVN. Janus Henderson Group PLC increased its stake in shares of Biohaven by 1,145.9% in the first quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after acquiring an additional 16,127,247 shares during the last quarter. BlackRock Inc. acquired a new stake in Biohaven during the second quarter valued at $196,574,000. Jupiter Topco LLC acquired a new stake in Biohaven during the second quarter valued at $127,852,000. Suvretta Capital Management LLC grew its stake in Biohaven by 83.0% in the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company's stock valued at $116,140,000 after purchasing an additional 4,666,666 shares in the last quarter. Finally, Infinitum Asset Management LLC grew its stake in Biohaven by 267.6% in the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company's stock valued at $70,562,000 after purchasing an additional 4,550,000 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source